logo
Wellgistics Health Secures $50M Credit Facility and Launches XRP-Powered Payment Initiative

Wellgistics Health Secures $50M Credit Facility and Launches XRP-Powered Payment Initiative

Business Upturn08-05-2025
Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) — Wellgistics Health, Inc. (NASDAQ: WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner.
This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.
'At Wellgistics Health, we challenge the idea that healthcare has to be tethered to legacy systems, bloated intermediaries, and slow-moving money,' said Brian Norton, CEO of Wellgistics Health. 'We are developing a platform that connects manufacturers directly to pharmacies and patients-bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that's long been starved of all three. I believe that the future winners in healthcare won't be the companies with the biggest buildings…they'll be those with the fastest rails, cleanest data, and most efficient platforms. We're betting on infrastructure…not inertia.'
Why XRP? Why Now?
We believe that there are certain advantages to integrating XRP and its related infrastructure into its healthcare ecosystem. These include, among others: Speed: XRP settles transactions in 3-5 seconds vs. 1-3 days for ACH or wire transfers, allowing for near real-time settlement among pharmacies, suppliers, and manufacturers.
XRP settles transactions in 3-5 seconds vs. 1-3 days for ACH or wire transfers, allowing for near real-time settlement among pharmacies, suppliers, and manufacturers. Cost: Less than $0.0002 per transfer vs. $10-$30 for standard bank wires.
Less than $0.0002 per transfer vs. $10-$30 for standard bank wires. Transparency: All transactions are logged on the XRP Ledger for real-time compliance, rebate tracking, and auditability.
All transactions are logged on the XRP Ledger for real-time compliance, rebate tracking, and auditability. Scope : Supports global vendor payouts with significantly low foreign exchange and wire transfer fees.
: Supports global vendor payouts with significantly low foreign exchange and wire transfer fees. Flexibility: Allows for XRP-backed lines of credit to support independent pharmacy liquidity.
These benefits will support faster vendor payments, performance-based rebates, and embedded liquidity tools for pharmacies and manufacturers in the Wellgistics ecosystem.
Use Cases Across the Ecosystem Real-time settlement between pharmacies, suppliers, and manufacturers
Smart rebates calculated automatically based on real-world data
XRP-backed credit lines to enhance liquidity for independent pharmacies
Global vendor payouts with near-zero foreign transaction and wire costs
Immutable compliance layer supporting DSCSA reporting and pricing validation
'We're working to unlock capital velocity with surgical precision,' said Mark DiSiena, CFO of Wellgistics Health. 'We believe that our XRP-powered infrastructure will allow us to run leaner, faster, and with more control than any of our peers in pharma infrastructure.'
The Market Is Moving-And Wellgistics Intends to Lead
XRP is gaining momentum across global institutions, as demonstrated by the following: CME Group to launch XRP futures for institutional access
→ CME will launch cash-settled XRP futures contracts in May 2025 to meet rising institutional demand.¹ Mastercard identifies XRP as a bridge currency for cross-border payments
→ Mastercard's 2025 report highlights XRP as a top solution for global remittances and cost efficiency.² Ripple acquires prime brokerage firm Hidden Road for $1.25B
→ This landmark acquisition expands XRP's footprint in institutional liquidity and asset servicing.³ Ripple receives regulatory licensing in Dubai
→ Ripple became the first blockchain payment provider licensed by the DFSA to operate crypto-based financial services in the UAE.⁴ Ripple expands real-world cross-border payment corridors in Brazil and Portugal
→ Ripple now enables live XRP-powered remittances between LATAM and Europe through its partnership with Unicâmbio.⁵
'Others are waiting for change. We're building it,' Norton added. 'I strongly believe that our XRP initiative positions Wellgistics Health years ahead of the curve-and squarely at the center of where healthcare and fintech converge.'
About Wellgistics Health
Wellgistics Health, Inc. (NASDAQ:WGRX) is a publicly traded healthcare infrastructure company transforming how medications move, get priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a growing network of more than 6,000 independent pharmacies nationwide.
Wellgistics Health delivers real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment models, while equipping pharmacies with embedded financial, clinical, and digital tools. Its integrated platform supports a wide range of therapeutic categories-from specialty-lite to maintenance meds-by eliminating friction, accelerating reimbursements, and creating direct, transparent pathways between manufacturers, providers, pharmacies, and patients.
For more information, visit: www.wellgisticshealth.com .
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov .
Media Contact: [email protected]
Investor Relations: [email protected]
References CME Group Press Release: CME to Launch XRP Futures AInvest: Mastercard Identifies XRP as Bridge Currency Reuters: Ripple Acquires Hidden Road for $1.25B BusinessWire: Ripple Licensed by DFSA in Dubai PYMNTS: Ripple Launches Portugal-Brazil Corridor
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citi Raised the Firm's PT on JD.com (JD), Kept a Buy Rating
Citi Raised the Firm's PT on JD.com (JD), Kept a Buy Rating

Yahoo

time3 minutes ago

  • Yahoo

Citi Raised the Firm's PT on JD.com (JD), Kept a Buy Rating

Inc. (NASDAQ:JD) is one of the Undervalued Cyclical Stocks to Buy According to Hedge Funds. On August 14, Citi analyst Alicia Yap raised the firm's price target on Inc. (NASDAQ:JD) from $42 to $44, while maintaining a Buy rating on the stock. The improved sentiment for the company follows its announcement of robust fiscal second-quarter 2025 results. Inc. (NASDAQ:JD) delivered RMB356.7 billion in revenue for the quarter, up 22.4% year-over-year, exceeding Wall Street estimates. Management noted that its Retail segment showed solid performance with revenue growing 20.6% and operating margins improving 4.5%. This was its highest margin in any promotional quarter. A wide and imposing view of a supply chain distribution center, illustrating the company's technology capabilities. Inc. (NASDAQ:JD) is an e-commerce company operating through its retail mobile apps and website, offering online retail and marketplace services. While we acknowledge the potential of JD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

What To Expect From Premier's (PINC) Q2 Earnings
What To Expect From Premier's (PINC) Q2 Earnings

Yahoo

time14 minutes ago

  • Yahoo

What To Expect From Premier's (PINC) Q2 Earnings

Healthcare tech company Premier (NASDAQ:PINC) will be reporting earnings this Tuesday morning. Here's what you need to know. Premier beat analysts' revenue expectations by 7.4% last quarter, reporting revenues of $261.4 million, down 8.9% year on year. It was a very strong quarter for the company, with a beat of analysts' EPS estimates and an impressive beat of analysts' full-year EPS guidance estimates. Is Premier a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Premier's revenue to decline 28.5% year on year to $250.4 million, a reversal from the 2.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.34 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Premier has missed Wall Street's revenue estimates four times over the last two years. Looking at Premier's peers in the healthcare technology for providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Privia Health delivered year-on-year revenue growth of 23.4%, beating analysts' expectations by 10.9%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Privia Health traded up 4% following the results while Omnicell's stock price was unchanged. Read our full analysis of Privia Health's results here and Omnicell's results here. There has been positive sentiment among investors in the healthcare technology for providers segment, with share prices up 7.2% on average over the last month. Premier is up 19.2% during the same time and is heading into earnings with an average analyst price target of $22.33 (compared to the current share price of $24.95). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio

Netflix (NFLX) Keeps Momentum with Strong Content Pipeline, Says Piper Sandler
Netflix (NFLX) Keeps Momentum with Strong Content Pipeline, Says Piper Sandler

Yahoo

time33 minutes ago

  • Yahoo

Netflix (NFLX) Keeps Momentum with Strong Content Pipeline, Says Piper Sandler

Netflix Inc. (NASDAQ:NFLX) is one of the best big tech stocks to buy right now. In a late-July note, Piper Sandler analyst Thomas Champion maintained a Buy rating on Netflix and kept his price target at $1,500. Champion's positive stance is based on recent improvements in viewership trends and a strong content pipeline. The analyst argues that June's Nielsen's Top 10 Viewership data showed a solid rebound in Netflix's audience numbers after a period of softness. He linked the turnaround to the launch of popular titles such as Ginny & Georgia Season 3, Blindspot, and Squid Game Season 3. Netflix Netflix has a heavy slate for the second half of the year, with new seasons of Stranger Things and Bridgerton expected to draw in more subscribers and keep momentum going. Champion also pointed to growth in Netflix's advertising business as another potential revenue driver. According to the analyst, the company's subscriber and revenue targets remain within reach, and the combination of popular content and new monetization avenues supports the current bullish outlook on the stock. Netflix Inc. (NASDAQ:NFLX) is a global streaming entertainment service that offers a diverse array of movies, TV shows, games, and more, with unlimited viewing on internet-connected devices. While we acknowledge the potential of NFLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Defensive Stocks to Invest in According to Analysts and 10 Best Large Cap Tech Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey. Inicia sesión para acceder a tu cartera de valores

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store